Total Payments
$1.1M
2024 Payments
$117,286
Companies
23
Transactions
286
Medicare Patients
872
Medicare Billing
$110,579
Payment Breakdown by Category
Consulting$918,242 (86.6%)
Other$92,139 (8.7%)
Travel$42,748 (4.0%)
Research$3,814 (0.4%)
Food & Beverage$3,279 (0.3%)
Royalty/License$612.72 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $918,242 | 108 | 86.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $90,579 | 94 | 8.5% |
| Travel and Lodging | $42,748 | 35 | 4.0% |
| Unspecified | $3,814 | 2 | 0.4% |
| Food and Beverage | $3,279 | 45 | 0.3% |
| Honoraria | $1,560 | 1 | 0.1% |
| Royalty or License | $612.72 | 1 | 0.1% |
Payments by Type
General
$1.1M
284 transactions
Research
$3,814
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $647,400 | 21 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $155,303 | 124 | $0 (2024) |
| Daiichi Sankyo Inc. | $66,146 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38,824 | 30 | $0 (2024) |
| GlaxoSmithKline, LLC. | $32,812 | 14 | $0 (2024) |
| AstraZeneca AB | $16,650 | 8 | $0 (2023) |
| United Therapeutics Corporation | $11,996 | 25 | $0 (2024) |
| Amgen Inc. | $11,094 | 11 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $10,981 | 9 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $8,380 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $117,286 | 88 | Boehringer Ingelheim International GmbH ($46,460) |
| 2023 | $153,493 | 86 | Boehringer Ingelheim International GmbH ($47,342) |
| 2022 | $293,136 | 92 | AstraZeneca Pharmaceuticals LP ($165,200) |
| 2021 | $495,360 | 19 | AstraZeneca Pharmaceuticals LP ($468,200) |
| 2020 | $1,560 | 1 | CSL Behring ($1,560) |
All Payment Transactions
286 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 12/17/2024 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $3,300.00 | General |
| 12/11/2024 | CSL Behring | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 12/11/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $114.48 | General |
| 11/29/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: RESPIRATORY | ||||||
| 11/29/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: RESPIRATORY | ||||||
| 11/26/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 11/21/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 11/19/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $479.96 | General |
| Category: RESPIRATORY | ||||||
| 11/16/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $103.95 | General |
| Category: RESPIRATORY | ||||||
| 11/16/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $52.67 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $54.10 | General |
| Category: RESPIRATORY | ||||||
| 11/15/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $979.50 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Travel and Lodging | In-kind items and services | $733.37 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Consulting Fee | Cash or cash equivalent | $2,925.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $650.00 | General |
| 10/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,480.00 | General |
| 09/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $129.37 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 09/18/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | Boehringer Ingelheim International GmbH | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,025.00 | General |
| 09/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,437.50 | General |
| 09/12/2024 | Chiesi USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,962.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A COHORT STUDY OF EARLY-ONSET PULMONARY EVENTS IN PATIENTS WITH ALK+ NSCLC TREATED WITH BRIGATINIB OR OTHER TYROSINE KINASE INHIBITORS | Takeda Pharmaceuticals U.S.A., Inc. | $3,814 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 387 | 612 | $271,545 | $52,306 |
| 2022 | 4 | 262 | 414 | $171,680 | $32,934 |
| 2021 | 3 | 199 | 280 | $115,325 | $22,939 |
| 2020 | 1 | 24 | 35 | $14,000 | $2,400 |
Total Patients
872
Total Services
1,341
Medicare Billing
$110,579
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 216 | 423 | $169,200 | $32,881 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 94 | 94 | $56,400 | $10,288 | 18.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 30 | 47 | $25,145 | $5,266 | 20.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $12,000 | $2,303 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 32 | $8,800 | $1,569 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 149 | 290 | $116,000 | $22,617 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 56 | 56 | $33,600 | $6,034 | 18.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 45 | 55 | $15,125 | $2,793 | 18.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 12 | 13 | $6,955 | $1,490 | 21.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 99 | 161 | $64,400 | $13,295 | 20.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 56 | 56 | $33,600 | $6,524 | 19.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 44 | 63 | $17,325 | $3,119 | 18.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 24 | 35 | $14,000 | $2,400 | 17.1% |
About Dr. Toby Maher, MD
Dr. Toby Maher, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/25/2020. The National Provider Identifier (NPI) number assigned to this provider is 1982221958.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Toby Maher, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $117,286 received in 2024. These payments were reported across 286 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($918,242).
As a Medicare-enrolled provider, Maher has provided services to 872 Medicare beneficiaries, totaling 1,341 services with total Medicare billing of $110,579. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 06/25/2020
- Last Updated 11/27/2023
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1982221958
Products in Payments
- OFEV (Drug) $156,831
- Enhertu (Drug) $50,781
- ENHERTU (Drug) $15,366
- ALUNBRIG (Drug) $3,249
- BENLYSTA (Biological) $2,925
- TYVASO (Drug) $2,127
- NUCALA (Biological) $31.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Pulmonary Disease $646,650
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
Pulmonary Disease $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Pulmonary Disease $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Pulmonary Disease $207,817
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942
Pulmonary Disease $172,942
Roy Artal, M.d, M.D
Pulmonary Disease — Payments: $151,187
Pulmonary Disease $151,187